Literature DB >> 17662596

Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene.

Josie L Falany1, Charles N Falany.   

Abstract

Sulfation is important in the metabolism and inactivation of steroidal compounds and hormone replacement therapeutic (HRT) agents in human tissues. Although generally inactive, many steroid sulfates are hydrolyzed to their active forms by sulfatase activity. Therefore, the specific sulfotransferase (SULT) isoforms and the levels of steroid sulfatase (STS) activity in tissues are important in regulating the activity of steroidal and HRT compounds. Tibolone (Tib) is metabolized to three active metabolites and all four compounds are readily sulfated. Tib and the Delta4-isomer are sulfated at the 17beta-OH group by SULT2A1 and the 17-sulfates are resistant to hydrolysis by human placental STS. 3alpha-OH and 3beta-OH Tib can form both 3- and 17-monosulfates as well as disulfates. Only the 3beta-sulfates are susceptible to STS hydrolysis. Raloxifene monosulfation was catalyzed by at least seven SULT isoforms and SULT1E1 also synthesizes raloxifene disulfate. SULT1E1 forms both monosulfates in a ratio of approximately 8:1 with the more abundant monosulfate migrating on HPLC identical to the SULT2A1 synthesized monosulfate. The raloxifene monosulfate formed by both SULT isoforms is sensitive to STS hydrolysis whereas the low abundance monosulfate formed by SULT1E1 is resistant. The benzothiophene sulfates of raloxifene and arzoxifene were hydrolyzed by STS whereas the raloxifene 4'-phenolic sulfate was resistant. These results indicate that tissue specific expression of SULT isoforms and STS could be important in the inactivation and regeneration of the active forms of HRT agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662596      PMCID: PMC2697607          DOI: 10.1016/j.jsbmb.2007.03.046

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  41 in total

1.  Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.

Authors:  V C Jordan; M Morrow
Journal:  BMJ       Date:  1999-08-07

2.  Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase.

Authors:  H Zhang; O Varlamova; F M Vargas; C N Falany; T S Leyh; O Varmalova
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

3.  Identification and characterization of cytosolic sulfotransferases in normal human endometrium.

Authors:  J L Falany; R Azziz; C N Falany
Journal:  Chem Biol Interact       Date:  1998-02-20       Impact factor: 5.192

4.  Regulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells.

Authors:  A Kotov; J L Falany; J Wang; C N Falany
Journal:  J Steroid Biochem Mol Biol       Date:  1999-02       Impact factor: 4.292

Review 5.  Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.

Authors:  Jorge R Pasqualini; Gérard S Chetrite
Journal:  J Steroid Biochem Mol Biol       Date:  2005-02       Impact factor: 4.292

6.  Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.

Authors:  P Kenemans; L Speroff
Journal:  Maturitas       Date:  2005-05-16       Impact factor: 4.342

Review 7.  Enzymology of human cytosolic sulfotransferases.

Authors:  C N Falany
Journal:  FASEB J       Date:  1997-03       Impact factor: 5.191

Review 8.  Steroid sulfatase: molecular biology, regulation, and inhibition.

Authors:  M J Reed; A Purohit; L W L Woo; S P Newman; B V L Potter
Journal:  Endocr Rev       Date:  2004-11-23       Impact factor: 19.871

9.  Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications.

Authors:  J R Pasqualini; G S Chetrite
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

10.  Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines.

Authors:  J L Falany; C N Falany
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

View more
  7 in total

1.  High accuracy in silico sulfotransferase models.

Authors:  Ian Cook; Ting Wang; Charles N Falany; Thomas S Leyh
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

2.  Structural rearrangement of SULT2A1: effects on dehydroepiandrosterone and raloxifene sulfation.

Authors:  Ian T Cook; Thomas S Leyh; Susan A Kadlubar; Charles N Falany
Journal:  Horm Mol Biol Clin Investig       Date:  2010

3.  Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Authors:  Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Peter M Scarbrough; Oana I Craciunescu; Janet K Horton; Holly K Dressman; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914

4.  Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie".

Authors:  Zoe Riches; Emma L Stanley; Jackie C Bloomer; Michael W H Coughtrie
Journal:  Drug Metab Dispos       Date:  2009-08-13       Impact factor: 3.922

5.  24-hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver x receptor activation.

Authors:  Ian T Cook; Zofia Duniec-Dmuchowski; Thomas A Kocarek; Melissa Runge-Morris; Charles N Falany
Journal:  Drug Metab Dispos       Date:  2009-07-09       Impact factor: 3.922

6.  Pharmacokinetics, tissue distribution and excretion of verticinone from F. hupehensis in rats.

Authors:  Xiao Wu; Jian-Guo Sun; Ying Peng; Yan Liang; Guang-Ji Wang; Hui Chen; Ji-Zhou Wu; Peng Zhang
Journal:  Molecules       Date:  2014-12-10       Impact factor: 4.411

7.  Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma.

Authors:  Borbála Vincze; Bence Kapuvári; Nóra Udvarhelyi; Zsolt Horváth; Zoltán Mátrai; Ferenc Czeyda-Pommersheim; Krisztina Kőhalmy; Judit Kovács; Mariann Boldizsár; István Láng; Miklós Kásler
Journal:  Springerplus       Date:  2015-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.